宫颈癌患者特定抗聚糖抗体阳性并接受近距离放疗与更好生存相关
在568例秘鲁宫颈癌患者中检测抗聚糖抗体,84.5%接受外照射加近距离放疗,15.5%仅外照射。III期患者仅外照射生存更差(HR 6.4,p<0.001),特定抗聚糖抗体阳性者无进展生存和疾病特异性生存更好(最佳HR=0.49,p=0.0008)。
要点
- III期宫颈癌仅接受外照射者生存显著差于接受外照射加近距离放疗者。
- 特定抗聚糖抗体阳性与更好的无进展生存和疾病特异性生存相关。
- 研究提示抗聚糖抗体可能作为宫颈癌预后标志物。
核心结论
- 特定抗聚糖抗体阳性且接受近距离放疗的宫颈癌患者无进展生存和疾病特异性生存更好。
研究设计与样本
- 研究纳入276例II期和292例III期秘鲁宫颈癌患者,用Luminex多重聚糖阵列检测血清抗聚糖抗体,并用Cox回归分析生存关联。
主要发现
- 在177种聚糖中检测到针对50种(28.3%)的抗聚糖抗体。
- 568例患者中84.5%接受外照射加近距离放疗,15.5%仅接受外照射。
- III期患者仅外照射与更差生存显著相关(HR 6.4,p<0.001)。
- 匹配治疗方式后,III期患者生存显著差于II期患者(外照射加近距离放疗组HR=2.8)。
- 针对血型H、Lewis、Ganglio、Isoglobo、lacto和唾液酸化四糖抗原的多种抗聚糖抗体阳性者无进展生存和疾病特异性生存更好(最佳HR=0.49,最佳p=0.0008)。
临床怎么用
- 宫颈癌患者应接受外照射加近距离放疗以改善生存。
- 抗聚糖抗体检测可能有助于识别预后更好的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To measure anti-glycan antibodies (AGA) in cervical cancer (CC) patient sera and assess their effect on therapeutic outcome. PATIENTS AND METHODS: Serum AGA was measured in 276 stage II and 292 stage III Peruvian CC patients using a high content and throughput Luminex multiplex glycan array (LMGA) containing 177 glycans. Association with disease-specific survival (DSS) and progression free survival (PFS) were analyzed using Cox regression. RESULTS: AGAs were detected against 50 (28.3%) of the 177 glycans assayed. Of the 568 patients, 84.5% received external beam radiation therapy (EBRT) plus brachytherapy (BT), while 15.5% only received EBRT. For stage-matched patients (Stage III), receiving EBRT alone was significantly associated with worse survival (HR 6.4, p < 0.001). Stage III patients have significantly worse survival than Stage II patients after matching for treatment (HR = 2.8 in EBRT+BT treatment group). Furthermore, better PFS and DSS were observed in patients positive for AGA against multiple glycans belonging to the blood group H, Lewis, Ganglio, Isoglobo, lacto and sialylated tetrarose antigens (best HR = 0.49, best p = 0.0008). CONCLUSIONS: Better PFS and DSS are observed in cervical cancer patients that are positive for specific antiglycan antibodies and received brachytherapy.
引用
- Purohit S, Ferris DG, Alvarez M, et al. Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy. Gynecol Oncol. 2020. PMID: 31955861. doi:10.1016/j.ygyno.2020.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。